BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36410237)

  • 21. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
    Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
    J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Interval Between Neoadjuvant Chemoradiation and Surgery Upon Morbidity and Survival of Patients with Squamous Cell Carcinoma of Thoracic Esophagus.
    Furukawa T; Hamai Y; Hihara J; Emi M; Yamakita I; Ibuki Y; Kurokawa T; Okada M
    Anticancer Res; 2018 Sep; 38(9):5239-5245. PubMed ID: 30194173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base.
    Al-Sukhni E; Gabriel E; Attwood K; Kukar M; Nurkin SJ; Hochwald SN
    J Am Coll Surg; 2016 Dec; 223(6):784-792.e1. PubMed ID: 27641320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation of the post-neoadjuvant staging system of the American joint committee on cancer, 8th edition, in patients treated with neoadjuvant chemoradiotherapy followed by curative esophagectomy for localized esophageal squamous cell carcinoma.
    Kang J; Lee HP; Kim HR; Kim JH; Jung HY; Lee GH; Song HJ; Kim DH; Choi KD; Ahn JY; Ryu JS; Cho KJ; Lee MY; Kim SB; Kim YH; Park SR
    Surg Oncol; 2020 Dec; 35():491-497. PubMed ID: 33130441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-term outcome of Ivor Lewis esophagectomy following neoadjuvant chemoradiation versus perioperative chemotherapy in patients with locally advanced adenocarcinoma of the esophagus and gastroesophageal junction: a propensity score-matched analysis.
    Plum PS; Damanakis A; Buschmann L; Ernst A; Datta RR; Schiffmann LM; Zander T; Fuchs H; Chon SH; Alakus H; Schröder W; Hölscher AH; Bruns CJ; Bludau M
    J Cancer Res Clin Oncol; 2022 May; 148(5):1223-1234. PubMed ID: 34223965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does Neutrophil-to-Lymphocyte Ratio (NLR) Predict Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma?
    Anand S; Bhati G; Gurram R; Gnanasekaran S; Kate V; Pottakkat B; Kalayarasan R
    J Gastrointest Cancer; 2021 Jun; 52(2):659-665. PubMed ID: 32607960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients.
    Samson P; Robinson C; Bradley J; Lockhart AC; Puri V; Broderick S; Kreisel D; Krupnick AS; Patterson GA; Meyers B; Crabtree T
    J Thorac Oncol; 2016 Dec; 11(12):2227-2237. PubMed ID: 27544058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant Chemotherapy Is Associated With Improved Overall Survival in Locally Advanced Rectal Cancer After Achievement of a Pathologic Complete Response to Chemoradiation.
    Shahab D; Gabriel E; Attwood K; Ma WW; Francescutti V; Nurkin S; Boland PM
    Clin Colorectal Cancer; 2017 Dec; 16(4):300-307. PubMed ID: 28420585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer.
    de Heer EC; Hulshoff JB; Klerk D; Burgerhof JGM; de Groot DJA; Plukker JTM; Hospers GAP
    Ann Surg Oncol; 2017 Jul; 24(7):1811-1820. PubMed ID: 28188501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome?
    Chiu CH; Chao YK; Chang HK; Tseng CK; Chan SC; Liu YH; Chen WH
    Ann Surg Oncol; 2013 Dec; 20(13):4245-51. PubMed ID: 23959050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation.
    Klevebro F; Johnsen G; Johnson E; Viste A; Myrnäs T; Szabo E; Jacobsen AB; Friesland S; Tsai JA; Persson S; Lindblad M; Lundell L; Nilsson M
    Eur J Surg Oncol; 2015 Jul; 41(7):920-6. PubMed ID: 25908010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
    Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant versus definitive chemoradiation in locally advanced esophageal cancer for patients of advanced age or significant comorbidities.
    Jensen GL; Hammonds KP; Haque W
    Dis Esophagus; 2023 Jan; 36(2):. PubMed ID: 35901451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Upfront surgery and pathological stage-based adjuvant chemoradiation strategy in locally advanced esophageal squamous cell carcinoma.
    Chen HS; Hsu PK; Liu CC; Wu SC
    Sci Rep; 2018 Feb; 8(1):2180. PubMed ID: 29391589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patterns of Care and Outcomes of Elderly Esophageal Cancer Patients Not Meeting Age-based Criteria of the CROSS Trial.
    Verma V; Haque W; Zheng D; Osayande F; Lin C
    Am J Clin Oncol; 2019 Jan; 42(1):67-74. PubMed ID: 30216194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
    Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
    Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome of Patients Treated Within and Outside a Randomized Clinical Trial on Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: Extrapolation of a Randomized Clinical Trial (CROSS).
    Toxopeus E; van der Schaaf M; van Lanschot J; Lagergren J; Lagergren P; van der Gaast A; Wijnhoven B
    Ann Surg Oncol; 2018 Aug; 25(8):2441-2448. PubMed ID: 29948420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer.
    Blackham AU; H Naqvi SM; Schell MJ; Jin W; Gangi A; Almhanna K; Fontaine JP; Hoffe SE; Frakes J; Venkat P; Pimiento JM
    J Surg Oncol; 2018 Feb; 117(2):150-159. PubMed ID: 28833197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Lymph Node Yield on Overall Survival in Patients Treated With Neoadjuvant Chemoradiotherapy Followed by Esophagectomy for Cancer: A Population-based Cohort Study in the Netherlands.
    Visser E; van Rossum PSN; Ruurda JP; van Hillegersberg R
    Ann Surg; 2017 Nov; 266(5):863-869. PubMed ID: 28742691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic Value of the Circumferential Resection Margin in Esophageal Cancer Patients After Neoadjuvant Chemoradiotherapy.
    Hulshoff JB; Faiz Z; Karrenbeld A; Kats-Ugurlu G; Burgerhof JG; Smit JK; Plukker JT
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1301-9. PubMed ID: 26314875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.